DPS GROSS MARGINS FROM CAPITATION BUSINESS WERE 22.5%
DPS GROSS MARGINS FROM CAPITATION BUSINESS WERE 22.5% in 1993, according to information provided by SmithKline Beecham to its shareholders about SB's $2,3 bil, acquisition of Diversified Pharmaceutical Services, The May 20 letter to shareholders discloses that DPS capitation revenues of $79.4 mil. in 1993 were offset by $64.8 mil. in costs for the purchase of drug products used in the capitation programs. The company's gross profits from capitation were $14.6 mil. A capitation business was initiated by DPS in 1993.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth